Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Shares Issued
Ratios

Immuneering (IMRX) Leases (2020 - 2024)

Immuneering has reported Leases over the past 5 years, most recently at $3.7 million for Q3 2024.

  • Quarterly results put Leases at $3.7 million for Q3 2024, down 8.21% from a year ago — trailing twelve months through Sep 2024 was $3.7 million (down 8.21% YoY), and the annual figure for FY2023 was $4.0 million, down 9.35%.
  • Leases for Q3 2024 was $3.7 million at Immuneering, down from $3.8 million in the prior quarter.
  • Over the last five years, Leases for IMRX hit a ceiling of $5.3 million in Q4 2021 and a floor of $537181.0 in Q3 2021.
  • Median Leases over the past 5 years was $4.1 million (2023), compared with a mean of $3.6 million.
  • Biggest five-year swings in Leases: soared 768.4% in 2021 and later dropped 17.21% in 2022.
  • Immuneering's Leases stood at $613103.0 in 2020, then soared by 768.4% to $5.3 million in 2021, then dropped by 17.21% to $4.4 million in 2022, then dropped by 9.35% to $4.0 million in 2023, then dropped by 6.19% to $3.7 million in 2024.
  • The last three reported values for Leases were $3.7 million (Q3 2024), $3.8 million (Q2 2024), and $3.9 million (Q1 2024) per Business Quant data.